Can metformin be added to a pregnant woman's regimen, and what are the appropriate indications and timing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Metformin Should Generally NOT Be Added During Pregnancy for Type 2 Diabetes, But May Be Considered for Gestational Diabetes When Insulin Alone Is Insufficient

For pregnant women with preexisting type 2 diabetes already on insulin, the most recent 2025 Endocrine Society/European Society of Endocrinology guideline explicitly recommends AGAINST routinely adding metformin 1. This represents the highest-quality, most recent guidance available and should guide clinical decision-making for this population.

Clinical Algorithm for Metformin Use in Pregnancy

Type 2 Diabetes (Preexisting)

  • Insulin remains the preferred and primary treatment 2
  • Do NOT routinely add metformin to insulin therapy 1
  • Women with T2DM have more severe insulin deficiency and resistance; metformin cannot substitute for insulin in this population 1
  • The 2025 guideline's recommendation against routine addition is based on concerns about:
    • Fetal growth restriction and increased small-for-gestational-age infants (doubled in one major trial) 1, 3
    • Decreased fetal skeletal muscle mass (demonstrated in primate studies at human-equivalent doses) 1
    • Uncertain long-term metabolic programming effects on offspring 1

Gestational Diabetes Mellitus (GDM)

  • Start with lifestyle modification (medical nutrition therapy and exercise) 2
  • If glycemic targets not met, insulin is the preferred first-line medication 2
  • Metformin should NOT be used as a first-line agent 2
  • Metformin may be considered as a second-line option when:
    • Lifestyle modification fails to achieve targets
    • Patient refuses insulin or has significant barriers to insulin use
    • Milder hyperglycemia (not severe GDM)
    • Lower BMI and later diagnosis (failure rates higher with early diagnosis, higher glucose, higher BMI, or prior GDM history) 4, 5

Polycystic Ovary Syndrome (PCOS)

  • Discontinue metformin by the end of the first trimester if used for ovulation induction 2
  • No evidence supports continuing metformin throughout pregnancy for PCOS 6
  • Metformin does not prevent GDM in women with PCOS 2

Critical Safety Considerations

Placental Transfer and Fetal Exposure

Metformin crosses the placenta extensively, achieving fetal levels equal to or higher than maternal levels due to high OCT3 transporter expression in second and third trimesters 1. It concentrates 1000-fold in fetal and placental mitochondria 1. This creates direct fetal exposure with potential for:

  • Mitochondrial complex 1 inhibition
  • AMPK activation with nutrient restriction properties
  • mTOR pathway suppression affecting cell proliferation 1

Notably, placental transfer is poor in the first trimester, and metformin does NOT increase major malformation risk 1, 7.

Offspring Outcomes: Mixed Evidence

The long-term effects on children remain the most significant concern:

Concerning findings:

  • 9-year-old offspring in the Auckland MiG TOFU cohort exposed to metformin for GDM had higher weight, waist-to-height ratio, and waist circumference compared to insulin-exposed children 4, 6
  • Children exposed to metformin for maternal PCOS showed higher BMI and increased obesity at 4-10 years 4, 6
  • Meta-analyses show smaller neonates with accelerated postnatal growth and higher childhood BMI 4, 6

Reassuring findings:

  • The Adelaide MiG TOFU cohort showed no differences 6
  • MiTy Kids trial (T2DM population) showed no anthropometric differences at 24 months 6
  • No clear association with major birth defects or miscarriage 7

Maternal Benefits When Used

When metformin is used (primarily in GDM), benefits include:

  • Reduced maternal weight gain (1.5 kg less) 8
  • Lower insulin requirements 1, 3, 8
  • Reduced neonatal hypoglycemia 4, 6, 8
  • Fewer large-for-gestational-age infants 8
  • Lower NICU admission rates 8
  • Better maternal acceptability (oral route, lower cost, no hypoglycemia risk) 1

Maternal Risks

  • Increased small-for-gestational-age infants (RR 1.43-1.96) 3, 8
  • Gastrointestinal side effects 3
  • Treatment failure requiring insulin in 14-46% of GDM cases 6

Glycemic Targets During Pregnancy

When managing diabetes in pregnancy (regardless of medication):

  • Fasting glucose <95 mg/dL (5.3 mmol/L)
  • 1-hour postprandial <140 mg/dL (7.8 mmol/L) OR
  • 2-hour postprandial <120 mg/dL (6.7 mmol/L) 2

Common Pitfalls to Avoid

  1. Do not assume metformin is "natural" or safer than insulin - It has significant placental transfer and uncertain long-term offspring effects 1

  2. Do not use metformin as monotherapy in T2DM pregnancies - These women require insulin for adequate glycemic control 1

  3. Do not continue metformin from preconception PCOS treatment beyond first trimester - No benefit demonstrated and potential offspring risks exist 2

  4. Do not use metformin to prevent GDM - Multiple RCTs show it does not reduce GDM risk in high-risk women with obesity, PCOS, or insulin resistance 2, 6

  5. Monitor for small-for-gestational-age infants - This risk is consistently elevated with metformin use 3, 8

FDA Labeling Position

The FDA label acknowledges limited data but notes no clear association with major birth defects or miscarriage in published studies 7. However, it emphasizes that studies cannot definitively establish absence of risk due to methodological limitations 7. The label does not provide specific pregnancy recommendations, leaving clinical judgment to guideline-based evidence.

Bottom Line for Clinical Practice

The evidence hierarchy is clear: insulin first for all types of diabetes in pregnancy. For women with preexisting T2DM on insulin, do not routinely add metformin based on the 2025 Endocrine Society guideline 1. For GDM, metformin may serve as a second-line option after lifestyle modification when insulin is refused or impractical, but only with informed consent about uncertain long-term offspring effects and increased SGA risk. The decision must weigh short-term maternal and neonatal benefits against potential long-term metabolic programming concerns in offspring that remain incompletely understood.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.